Eli Lilly and Company (LLY)
NYSE: LLY · Real-Time Price · USD
925.81
+18.95 (2.09%)
At close: Nov 5, 2025, 4:00 PM EST
926.59
+0.78 (0.08%)
After-hours: Nov 5, 2025, 6:17 PM EST
Eli Lilly Revenue
Eli Lilly had revenue of $17.60B in the quarter ending September 30, 2025, with 53.87% growth. This brings the company's revenue in the last twelve months to $59.42B, up 45.41% year-over-year. In the year 2024, Eli Lilly had annual revenue of $45.04B with 32.00% growth.
Revenue (ttm)
$59.42B
Revenue Growth
+45.41%
P/S Ratio
13.71
Revenue / Employee
$1,264,251
Employees
47,000
Market Cap
828.96B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 45.04B | 10.92B | 32.00% |
| Dec 31, 2023 | 34.12B | 5.58B | 19.56% |
| Dec 31, 2022 | 28.54B | 223.00M | 0.79% |
| Dec 31, 2021 | 28.32B | 3.78B | 15.40% |
| Dec 31, 2020 | 24.54B | 2.22B | 9.95% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
| Abbott Laboratories | 43.84B |
LLY News
- 5 hours ago - Trump, Eli Lilly to announce weight loss drug price cut on Thursday, CBS reports - Reuters
- 13 hours ago - XtalPi Subsidiary Ailux Announces Strategic Collaboration with Lilly to Advance Bispecific Antibody Development - PRNewsWire
- 1 day ago - Obesity drugs may get Medicare access under deal with White House: reports - Market Watch
- 1 day ago - Lilly and Novo Nordisk near White House deal on obesity drug prices, Endpoints New reports - Reuters
- 2 days ago - Biotech is back. Here's why these rallying stocks belong in your portfolio now. - Market Watch
- 2 days ago - Lilly to build $3 billion Dutch plant to boost weight-loss pill production - Reuters
- 2 days ago - Lilly plans to build a new $3 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide - PRNewsWire
- 3 days ago - Where the blockbuster weight loss drug market stands today — and what's coming next - CNBC